The significant 39% increase in OMI's stock price is directly linked to the company's Q4 earnings surpassing expectations and its strategic focus on growth through Patient Direct and the Rotech acquisition. These factors are likely to enhance long-term shareholder value, positively impacting the stock in the short term.